

Thalidomide-Piperazine-PEG3-NH2 Biochemical

Thalidomide-Piperazine-PEG3-NH2

CATALOG #
AAA228340


PRODUCT SYNONYMS

Thalidomide-Piperazine-PEG3-NH2; S-217622 fumarate; Thalidomide-Piperazine-PEG3-NH2 biochemical


PRODUCT SPECIFICATIONS

Purity/Purification	98%
CAS	2357113-68-7
Solubility	<1mg/ml refers to the product slightly soluble or insoluble
In vitro	PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[2].
Preparation and Storage	Powder: -20 degree C for 3 years In solvent: -80 degree C for 2 years

IMAGES



Structure
Ensirelvir fumarate, CAS 2757470-18-9



Structure
Ensirelvir fumarate, CAS 2757470-18-9

ADDITIONAL INFORMATION

Related Product Information for Thalidomide-Piperazine-PEG3-NH2 biochemical	Thalidomide-Piperazine-PEG3-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.
References	- McKimm-Breschkin JL, et al. COVID-19, Influenza and RSV: Surveillance-informed prevention and treatment - Meeting report from an isirv-WHO virtual conference. Antiviral Res. 2022;197:105227. - Yuto Unoh, et al. Discovery of S-217622, a Non-Covalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19. bioRxiv 2022.01.26.477782.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.

